ARV Therapies and Therapeutic Strategies

INDEPENDENT REPORTING ON IAS 2017

COMPREHENSIVE EXPERT REVIEW AND DISCUSSION OF KEY PRESENTATIONS

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

WEEKLY ORAL MK-8591 PROTECTS MALE RHESUS MACAQUES AGAINST REPEATED LOW DOSE INTRARECTAL CHALLENGE WITH SHIVC109P3

M. Markowitz, A. Gettie, L. St. Bernard, H. Mohri, C.D. Andrews, A. Horowitz, J. Blanchard, B. Grasperge, L. Sun, K.L. Filigrove, D.J. Hazuda, J.A. Grobler

Abstract MOAX0203LB

SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN LOW-RISK HIV-UNINFECTED WOMEN AND MEN: HPTN 077

R. Landovitz, S. Li, B. Grinsztejn, H. Dawood, A. Liu, M. Magnus, M. Hosseinipour, R. Panchia, L. Cottle, G. Chau, P. Richardson, M. Marzinke, C. Hendrix, B. Tolley, A. Adeyeye, D. Burns, A. Rinehart, D. Margolis, M. McCauley, J. Eron

Abstract TUAC0106LB

MK-8591 (EFdA) GIVEN ONCE WEEKLY PROTECTIVE AGAINST SHIV CHALLENGE

- MK-8591 (EFdA) is a long acting nucleoside reverse transcriptase translocation inhibitor – half life 168 hr
- Reduces HIV RNA levels by >1.5 log after a single dose in humans

Methods[2]



Results

Grobler et al 2017 CROI, Seattle, WA 2.Markowitz M, et al. Matthews R, et al; 9th IAS, Paris, France, July 23-26, 2017; Abst. MOAX0203LB.

HPTN 077: SAFETY, TOLERABILITY, AND PK OF INJECTABLE CABOTEGRAVIR

Cohort 1:
30 mg po daily x 4 w
800 mg IM Q12W



Cohort 2:
30 mg po daily x 4 w
600 mg IM Q8W



Landovitz R, et al; 9th IAS, Paris, France, July 23-26, 2017; Abst. TUAC0106LB.